Bayer and Janssen Reached Settlement over Xarelto™

| By | Bayer, Drug Lawsuit, Janssen Pharamaceuticals
0
100

More than five years after the Xarelto™ litigation began, and with Bayer and Janssen Pharmaceuticals prevailing in all six cases that went to trial, the companies have reached an agreement in principle to settle in the amount of 775 million U.S. dollars.

The settlement amount will be shared equally between the two companies. It is expected that Bayer’s share will be partially offset by product liability insurance.

The settlement will resolve virtually all of the approximately 25,000 Xarelto™ claims in the US. The companies have reserved the right to withdraw from the settlement if certain participation rates of those who are eligible to participate are not satisfied.

Bayer continues to believe these claims are without merit and there is no admission of liability under the agreement. However, this favorable settlement allows the company to avoid the distraction and significant cost of continued litigation.

The safety profile of Xarelto™ remains positive and unchanged as confirmed time and again by regulatory agencies worldwide. Bayer remains committed to the more than 45 million patients who have been prescribed Xarelto™ worldwide and focused on developing new therapies that improve the lives and well-being of patients.

SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.